Document:

EX-10.7

 Exhibit 10.7 

ARS PHARMACEUTICALS, INC. 

EXECUTIVE EMPLOYMENT AGREEMENT 

for 
 KATHY SCOTT 

This Executive Employment Agreement (this “Agreement”) is made and entered into effective as of February 7, 2022 (the
“Effective Date”), by and between Kathleen Scott (“Executive”) and ARS Pharmaceuticals, Inc. (the “Company”). 

1. Employment by the Company. 

1.1 Position. Executive’s employment with the Company shall begin on February 16, 2022 or such date as otherwise
agreed to by Executive and the Company (such actual date Executive’s employment begins, the “Start Date”). Executive shall serve as the Company’s Chief Financial Officer, reporting to the Company’s Chief Executive
Officer. From the Start Date until March 15, 2022 or such other date as mutually agreed in writing between the Company and the Chief Executive Officer (“Transition Period”), Executive shall be employed on a part-time basis with
a 50% time commitment to the Company. Following the Transition Period, Executive shall be employed on a full-time basis with a 100% time commitment to the Company. During the term of Executive’s employment with the Company, Executive will
devote Executive’s best efforts and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities all in conformity with the Company’s policies applicable to senior
executives and general employment policies. 
 1.2 Duties and Location. Executive shall perform such duties as are customarily
associated with the position of Chief Financial Officer and such other duties as are assigned to Executive by the Company’s Chief Executive Officer. Executive’s primary work location shall be the Company’s office located in San Diego,
California, and Executive will travel as reasonably required by the Company for business purposes. 
 1.3 Policies and
Procedures. The employment relationship between the parties shall be governed by the general employment policies and practices of the Company and applicable state law, except that when the terms of this Agreement differ from or are in conflict
with the Company’s general employment policies or practices, this Agreement shall control. 
 2. Compensation. 

2.1 Base Salary. During the Transition Period, Executive shall receive an initial base salary at the annual rate of $195,000
(the “Base Salary”) reflecting a 50% part-time commitment. Following the Transition Period, once Executive becomes employed on a full-time basis with the Company, then Executive’s Base Salary shall be increased to an annual
rate of $390,000. Executive’s Base Salary shall be subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. 

2.2 Annual Bonus. During Executive’s employment, Executive will be 

  
 1. 

 
eligible for an annual discretionary bonus, subject to applicable payroll deductions and withholdings, and prorated for the number of days Executive remains continuously employed in a calendar
year (the “Annual Bonus”). Whether Executive receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Company’s Board of Directors (the “Board”) and/or the
Compensation Committee thereof in its discretion based upon the achievement of Company corporate and/or individual objectives and milestones that are determined in the sole discretion of the Board. Executive must continue to be employed through the
date the Annual Bonus is paid in order to earn such bonus. 
 2.3 Equity Grant; Change in Control. Subject to approval by the
Board, and pursuant to the Company’s 2018 Equity Incentive Plan (the “Plan”), the Company shall grant Executive an option to purchase 700,000 shares of the Company’s common stock at the fair market value as determined by
the Board as of the date of grant (the “Option”). The Option will be subject to the terms and conditions of the Plan and Executive’s grant agreement. Executive’s grant agreement will include a four year vesting schedule,
under which 25 percent of Executive’s shares will vest after twelve months of employment, with the remaining shares vesting monthly thereafter, until either the Option is fully vested or Executive’s employment ends, whichever occurs
first. In the event of a Change in Control during Executive’s Continuous Service (as such terms are defined in the Plan), then 100% of the shares underlying the Option will automatically accelerate and become exercisable. 

3. Standard Company Benefits. Executive shall, in accordance with Company policy and the terms and conditions of the applicable
Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive officers and other employees from time to time. Any such benefits shall be subject to the terms and
conditions of the governing benefit plans and policies and may be changed by the Company in its discretion. 
 4. Expenses.
The Company shall pay or reimburse Executive, on a monthly basis, for reasonable travel, entertainment, promotional and other expenses incurred by Executive in the performance of Executive’s business-related obligations under this Agreement
(collectively “Expenses”). To be eligible for reimbursement of any Expenses under this Agreement, Executive must submit timely detailed expense reports, receipts or other satisfactory evidence of payment for appropriate review
within 30 days of incurring such expense. The Company shall reimburse Executive promptly, but in no event later than thirty (30) days after Executive submits an expense report in accordance with the preceding sentence.  

5. Confidential Information Obligations. 

5.1 Confidential Information Agreement. As a condition of employment, and in consideration for the benefits provided for in this
Agreement, Executive agrees to execute and abide by the Company’s Employee Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”) attached hereto as Exhibit A.
In addition, Executive agrees to abide by the Company’s policies and procedures, as may be modified from time to time within the Company’s discretion. 

  
 2. 

 5.2 Third-Party Agreements and Information. Executive represents and warrants
that Executive’s employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executive’s duties to the Company without violating any
such agreement. Executive represents and warrants that Executive does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executive’s
employment by the Company, except as expressly authorized by that third party. During Executive’s employment by the Company, Executive will use in the performance of Executive’s duties only information that is generally known and used by
persons with training and experience comparable to Executive’s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive’s work for the
Company. 
 6. Outside Activities and Non-Competition During Employment. 

6.1 Outside Activities. Except with the prior written consent of the Company’s Chief Executive Officer, Executive will not
during the term of Executive’s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor; provided that Executive may participate in the
Permitted Outside Activities listed in Exhibit B hereto in accordance with the terms and conditions set forth therein. Executive may engage in civic and
not-for-profit activities so long as such activities do not materially interfere with the performance of Executive’s duties hereunder. Executive agrees not to
acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise. 

6.2 Non-Competition During Employment. Throughout Executive’s employment with the
Company, Executive will not, without the express written consent of the Chief Executive Officer, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venture, associate, representative or
consultant of any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its affiliates; provided, however, that
Executive may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or
regional securities exchange. 
 7. Termination of Employment; Severance Benefits. 

7.1 At-Will Employment. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause (as defined below) or advance notice. 

7.2 Termination Without Cause or Resignation for Good Reason. In the event Executive’s employment with the Company is
terminated by the Company without Cause (and other than as a result of Executive’s death or disability) or Executive resigns for Good Reason, such termination or resignation constitutes a “separation from service” (as defined under

  
 3. 

 
Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), and
provided that Executive satisfies the Release Requirement in Section 8 below, and remains in compliance with the terms of this Agreement and the Confidential Information Agreement, the Company shall provide Executive with the following
“Severance Benefits”: 
 7.2.1 Severance Payments. Severance pay in the form of continuation of
Executive’s final Base Salary for a period of twelve (12) months following termination, subject to required payroll deductions and tax withholdings (the “Severance Payments”). Subject to Section 9 below, the Severance
Payments shall be made on the Company’s regular payroll schedule in effect following Executive’s termination date; provided, however that any such payments that are otherwise scheduled to be made prior to the Release Effective Date (as
defined below) shall instead accrue and be made on the first administratively practicable payroll date following the Release Effective Date. For such purposes, Executive’s final Base Salary will be calculated prior to giving effect to any
reduction in Base Salary that would give rise to Executive’s right to resign for Good Reason. 
 7.2.2 Stock Vesting.
The vesting of all outstanding Stock Awards (as defined below) granted to Executive following the Effective Date held by Executive shall be accelerated such that the amount of shares vested under such Stock Awards shall equal that number of shares
that would have been vested if Executive had continued to render services to the Company for twelve (12) continuous months after the date of Executive’s termination of employment. “Stock Awards” shall mean any rights
granted by the Company to Executive following the Effective Date with respect to the common stock of the Company, including, without limitation, stock options, stock appreciation rights, restricted stock, stock bonuses and restricted stock units.

 7.2.3 Health Care Continuation Coverage Payments. 

(i) COBRA Premiums. If Executive timely elects continued coverage under COBRA, the Company will pay Executive’s COBRA premiums to
continue Executive’s coverage (including coverage for Executive’s eligible dependents, if applicable) (“COBRA Premiums”) through the period starting on the termination date and ending twelve (12) months after the
termination date (the “COBRA Premium Period”); provided, however, that the Company’s provision of such COBRA Premium benefits will immediately cease if during the COBRA Premium Period Executive becomes eligible for group health
insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer’s group health plan or
otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event. 

(ii) Special Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Executive or
Executive’s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Executive, on the first day of each calendar month 

  
 4. 

 
following the termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Executive’s eligible
dependents), subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for the remainder of the COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of
COBRA premiums. 
 7.3 Termination for Cause; Resignation Without Good Reason; Death or Disability. Executive will not be
eligible for, or entitled to any severance benefits, including (without limitation) the Severance Benefits listed in Section 7.2 above, if (i) Executive’s employment terminates for any reason prior to the first to occur of
(A) the first anniversary of the date of this Agreement or (B) the consummation of a Change in Control, (ii) the Company terminates Executive’s employment for Cause, (iii) Executive resigns Executive’s employment
without Good Reason, or (iv) Executive’s employment terminates due to Executive’s death or disability. 
 8.
Conditions to Receipt of Severance Benefits. To be eligible for the Severance Benefits pursuant to Section 7.2 above, Executive must satisfy the following release requirement (the “Release Requirement”): return to the
Company a signed and dated general release of all known and unknown claims in a termination agreement acceptable to the Company (the “Release”) within the applicable deadline set forth therein, but in no event later than forty-five
(45) calendar days following Executive’s termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the “Release Effective Date”). No
Severance Benefits will be provided hereunder prior to the Release Effective Date. Accordingly, if Executive refuses to sign and deliver to the Company an executed Release or signs and delivers to the Company the Release but exercises
Executive’s right, if any, under applicable law to revoke the Release (or any portion thereof), then Executive will not be entitled to any severance, payment or benefit under this Agreement. 

9. Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to
the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be
construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)),
Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment
hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a
“specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred
compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A,
such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month and one day 

  
 5. 

 
period measured from the date of Executive’s Separation from Service with the Company, (ii) the date of Executive’s death or (iii) such earlier date as permitted under
Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 9 shall be paid in a
lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the Company determines that any severance benefits provided
under this Agreement constitutes “deferred compensation” under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective date of the Release will not be deemed to have occurred any
earlier than the sixtieth (60th) date following the Separation From Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations
and guidance issued thereunder, if the applicable deadline for Executive to execute (and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence until the beginning of the second
calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A, amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the last day of the year following
the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Executive) during any one year may not effect amounts reimbursable or provided
in any subsequent year. The Company makes no representation that any or all of the payments described in this Agreement will be exempt from or comply with Code Section 409A and makes no undertaking to preclude Code Section 409A from
applying to any such payment.  
 10. Definitions. 

10.1 Cause. For the purposes of this Agreement, “Cause” means the occurrence of any one or more of the following:
(i) Executive’s conviction of or plea of guilty or nolo contendere to any felony or any crime of moral turpitude; (ii) Executive’s continued failure or refusal to follow lawful instructions of the Company or lawful
policies and regulations of the Company; (iii) Executive’s continued failure to faithfully and diligently perform the assigned duties of Executive’s employment with the Company; (iv) Executive’s violation of a fiduciary duty
or duty or loyalty owed to the Company or its affiliates; (v) unprofessional, unethical, immoral or fraudulent conduct by Executive that materially discredits the Company or its affiliates, or is materially detrimental to the reputation,
character and standing of the Company or its affiliates; or (vi) Executive’s material breach of this Agreement, the Confidential Information Agreement, or any written Company policies. An event described in Section 10.1(ii) through
Section 10.1(vi) herein shall not be treated as “Cause” until after Executive has been given written notice of such event, failure, conduct or breach and Executive fails to cure such event, failure, conduct or breach within 30
calendar days from such written notice; provided, however, that such 30 calendar day cure period shall not be required if the event, failure, conduct or breach is incapable of being cured. 

10.2 Good Reason. For purposes of this Agreement, Executive shall have “Good Reason” for resignation from employment
with the Company if any of the following actions are taken by the Company without Executive’s prior written consent: (i) a material reduction in Executive’s Base Salary, unless pursuant to a salary reduction program applicable

  
 6. 

 
generally to the Company’s senior executives; or (ii) a material reduction in Executive’s duties (including responsibilities and/or authorities), provided, however, that a
change in job position (including a change in title) or reporting line shall not be deemed a “material reduction” in and of itself unless Executive’s new duties are materially reduced from the prior duties. In order for Executive to
resign for Good Reason, each of the following requirements must be met: (iii) Executive must provide written notice to the Company within 30 calendar days after the first occurrence of the event giving rise to Good Reason setting forth the
basis for Executive’s resignation, (iv) Executive must allow the Company at least 30 calendar days from receipt of such written notice to cure such event, (v) such event is not reasonably cured within such 30 calendar day period (the
“Cure Period”), and (vi) Executive must resign from all positions Executive then holds with the Company and its affiliates not later than 30 calendar days after the expiration of the Cure Period. 

11. Dispute Resolution. To ensure the timely and economical resolution of disputes that may arise between Executive and the
Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by applicable law, Executive and the Company will
submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance, breach or enforcement of this
Agreement; or (ii) Executive’s employment with the Company (including but not limited to all statutory claims); or (iii) the termination of Executive’s employment with the Company (including but not limited to all
statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EXECUTIVE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING. The arbitrator
shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action
and bear on their final disposition. All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class
member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any
form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed
in a court of law rather than by arbitration. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS, Inc. (“JAMS”) in San Diego, California, or as otherwise agreed to
by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). Executive
and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party’s own expense. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of
the dispute; (ii) issue a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that Executive or
the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of

  
 7. 

 
law. This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the
California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to
mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event Executive intend to bring multiple claims, including one of the
Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. Nothing in this Section is intended to prevent either Executive or the Company from obtaining
injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction
and enforced accordingly. 
 12. General Provisions. 

12.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery
(including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

12.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect
any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

12.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 
 12.4
Complete Agreement. This Agreement, together with the Confidential Information Agreement, constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof and is the complete, final, and exclusive
embodiment of the Company’s and Executive’s agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and
it supersedes and replaces any other agreements or promises made to Executive by anyone concerning Executive’s employment terms, compensation or benefits, whether oral or written. It cannot be modified or amended except in a writing signed by a
duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s discretion in this Agreement. 

12.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more
than one party, but both of which taken together will constitute one and the same Agreement. 

  
 8. 

 12.6 Headings. The headings of the sections hereof are inserted for
convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 12.7 Successors and
Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of
Executive’s duties hereunder and Executive may not assign any of Executive’s rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

12.8 Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of
applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of
any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to
this Agreement. 
 12.9 Choice of Law. All questions concerning the construction, validity and interpretation of this
Agreement will be governed by the laws of the State of California. 
 [Signature Page Follows] 

  
 9. 

 IN WITNESS WHEREOF, this
Agreement shall be effective as of the Effective Date 
  

			
	ARS PHARMACEUTICALS, INC.
		
	By:	 	/s/ Richard Lowenthal
		 	Richard Lowenthal
		 	Chief Executive Officer
	
	EXECUTIVE
	
	/s/ Kathleen Scott
	Kathleen Scott

 [SIGNATURE PAGE TO EMPLOYMENT
AGREEMENT] 

 Exhibit A 

Employee Confidential Information and Inventions Assignment Agreement 

(separately attached) 

 Exhibit B 

Permitted Outside Activities 
 The Company
agrees that, during my employment, I may engage in outside services and activities (the “Permitted Outside Activities”): 
  

	 	•	 	 Member of Board of Directors of Dermata Therapeutics, and other private or public company board positions that do
not interfere or conflict with the performance of my duties and obligations to the Company. 

  

	 	•	 	 Completing the shut down process of Neurana Pharmaceuticals, Inc. 

As a condition to the Company’s consent to my participation in such outside activities during my employment with the Company, I hereby represent, warrant
and agree that: 
  

	 	1.	 I agree that, at all relevant times during my employment with the Company, my employment duties to the Company
shall take precedence over the Permitted Outside Activities, and such Permitted Outside Activities shall not interfere or conflict with the performance of my duties and obligations to the Company. 

 

	 	2.	 I understand and agree that, during my employment with the Company, the Company shall have the discretion to
determine whether my time commitment to such Permitted Outside Activities conflicts with my duties to the Company and to reasonably request changes to such outside time commitment by providing advance notice to me. 

 

	 	3.	 I will not use for any outside party’s benefit (or that of any other third parties), any information
relating to or arising out of my employment with or work on behalf of the Company. I will not utilize the funds, personnel, facilities, equipment, materials or other resources of the Company in performing the Permitted Outside Activities.

  

	 	4.	 I will not incorporate any of the Company’s intellectual property, confidential information or proprietary
information into the Permitted Outside Activities. Likewise, I will not incorporate any outside party’s intellectual property, confidential information or proprietary information into my work for the Company. 

 

	 	5.	 Without limiting the Company’s other rights and remedies, I agree that the Company’s consent to my
participation in such outside activities may be immediately withdrawn if the Company determines, in its sole discretion, that such activities compromise or threaten to compromise the Company’s or its affiliates’ business interests or
conflict with my duties or obligations to the Company or its affiliates, or upon breach of any of the foregoing statements. 

 Accepted
and agreed: 
  

	
	   

	Kathleen ScottEX-10.8

 Exhibit 10.8 

ARS PHARMACEUTICALS, INC. 

EXECUTIVE EMPLOYMENT AGREEMENT 

for 
 DR. SARINA TANIMOTO

 This Executive Employment Agreement (this “Agreement”) is made and entered into effective as of September 14,
2018 (the “Effective Date”), by and between Dr. Sarina Tanimoto (“Executive”) and ARS Pharmaceuticals, Inc. (the “Company”). 

1. Employment by the Company. 

1.1 Position. Executive shall serve as the Company’s Chief Medical Officer (“CMO”), reporting to
the Company’s Chief Executive Officer. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts, on a part-time (30%) basis, to the business of the Company, except for approved
vacation periods and reasonable periods of illness or other incapacities all in conformity with the Company’s policies applicable to senior executives and general employment policies. 

1.2 Duties and Location. Executive shall perform such duties as are customarily associated with the position of CMO and
such other duties as are assigned to Executive by the Company’s Chief Executive Officer or the Company’s Board of Directors (the “Board”). Executive’s primary office location shall be the Company’s office located
in San Diego, California, and Executive will travel as reasonably required by the Company for business purposes. 
 1.3 Policies
and Procedures. The employment relationship between the parties shall be governed by the general employment policies and practices of the Company and applicable California law, except that when the terms of this Agreement differ from or
are in conflict with the Company’s general employment policies or practices, this Agreement shall control. 
 2. Compensation.

 2.1 Base Salary. Executive shall receive a base salary at the annual rate of $120,000, less
standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. 
 2.2
Incentive Compensation. Subject to Board approval, the Company intends to establish an annual incentive compensation plan as soon as practicable following the execution of this Agreement. Once established, the details of the annual
incentive compensation plan, including the applicable terms and conditions of such plan and Executive’s eligibility to participate in such plan, will be provided to Executive. 

  
 1. 

 3. Standard Company Benefits. Executive
shall, in accordance with Company policy and the terms and conditions of the applicable Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive officers and other
employees from time to time. Any such benefits shall be subject to the terms and conditions of the governing benefit plans and policies and may be changed by the Company in its discretion. 

4. Expenses. The Company shall pay or reimburse Executive, on a monthly basis, for reasonable travel, entertainment,
promotional and other expenses incurred by Executive in the performance of his business-related obligations under this Agreement (collectively “Expenses”). To be eligible for reimbursement of any Expenses under this Agreement,
Executive must submit timely detailed expense reports, receipts or other satisfactory evidence of payment for appropriate review within 30 days of incurring such expense. The Company shall reimburse Executive promptly, but in no event later than
thirty (30) days after Executive submits an expense report in accordance with the preceding sentence. 
 5. Confidential Information
Obligations. 
 5.1 Confidential Information Agreement. As a condition of employment, and in consideration for the
benefits provided for in this Agreement, Executive agrees to continue to abide by the Company’s Employee Confidential Information and Inventions Assignment Agreement (the “Confidential Information Agreement”) that he previously
executed. In addition, Executive agrees to abide by the Company’s policies and procedures, as may be modified from time to time within the Company’s discretion. 

5.2 Third-Party Agreements and Information. Executive represents and warrants that Executive’s employment by the
Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executive’s duties to the Company without violating any such agreement. Executive represents
and warrants that Executive does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executive’s employment by the Company, except as
expressly authorized by that third party. During Executive’s employment by the Company, Executive will use in the performance of Executive’s duties only information that is generally known and used by persons with training and experience
comparable to Executive’s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive’s work for the Company. 

6. Outside Activities and Non-Competition During Employment. 

6.1 Outside Activities. Subject to the restrictions set forth herein and the Confidential Information Agreement, and only
with prior written disclosure to and consent of the Board, Executive may engage in other types of business or public activities; provided that the Board may rescind such consent, if the Board determines, in its sole discretion, that such other
activities compromise or threaten to compromise the Company’s or its affiliates’ business interests or conflict with Executive’s duties to the Company or its affiliates. 

  
 2. 

 6.2 Non-Competition During
Employment. Throughout Executive’s employment with the Company, Executive will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor,
investor, joint venturer, associate, representative or consultant of any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the
Company or its affiliates; provided, however, that Executive may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if
such securities are listed on any national or regional securities exchange. 
 7. Termination of Employment; Severance Benefits. 

7.1 At-Will Employment. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause (as defined below) or advance notice. 

7.2 Termination Without Cause or Resignation for Good Reason. In the event Executive’s employment with the Company
is terminated by the Company without Cause (and other than as a result of Executive’s death or disability) or Executive resigns for Good Reason, such termination or resignation constitutes a “separation from service” (as defined under
Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), and provided that Executive satisfies the Release
Requirement in Section 8 below, and remains in compliance with the terms of this Agreement and the Confidential Information Agreement, the Company shall provide Executive with the following “Severance Benefits”: 

7.2.1 Severance Payments. Severance pay in the form of continuation of Executive’s final base salary for a period of twelve
(12) months following termination, subject to required payroll deductions and tax withholdings (the “Severance Payments”). Subject to Section 9 below, the Severance Payments shall be made on the Company’s regular
payroll schedule in effect following Executive’s termination date; provided, however that any such payments that are otherwise scheduled to be made prior to the Release Effective Date (as defined below) shall instead accrue and be made on the
first administratively practicable payroll date following the Release Effective Date. For such purposes, Executive’s final base salary will be calculated prior to giving effect to any reduction in base salary that would give rise to
Executive’s right to resign for Good Reason. 
 7.2.2 Stock Vesting. The vesting of all outstanding Stock Awards (as
defined below) granted to Executive following the Effective Date held by Executive shall be accelerated such that the amount of shares vested under such Stock Awards shall equal that number of shares that would have been vested if Executive had
continued to render services to the Company for twelve (12) continuous months after the date of Executive’s termination of employment. “Stock Awards” shall mean any rights granted by the Company to Executive following the
Effective Date with respect to the common stock of the Company, including, without limitation, stock options, stock appreciation rights, restricted stock, stock bonuses and restricted stock units. 

  
 3. 

 7.2.3 Health Care Continuation
Coverage Payments. 
 (i) COBRA Premiums. If Executive timely elects continued coverage under COBRA,
the Company will pay Executive’s COBRA premiums to continue Executive’s coverage (including coverage for Executive’s eligible dependents, if applicable) (“COBRA Premiums”) through the period starting on the
termination date and ending twelve (12) months after the termination date (the “COBRA Premium Period”); provided, however, that the Company’s provision of such COBRA Premium benefits will immediately cease if during the COBRA
Premium Period Executive becomes eligible for group health insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes
covered under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event. 

(ii) Special Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Executive or
Executive’s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Executive, on the first day of each calendar month following the termination date, a fully taxable cash payment equal to the applicable COBRA
premiums for that month (including the amount of COBRA premiums for Executive’s eligible dependents), subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for the remainder of the COBRA Premium
Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums. 
 7.3
Termination for Cause; Resignation Without Good Reason; Death or Disability. Executive will not be eligible for, or entitled to any severance benefits, including (without limitation) the Severance Benefits listed in Section 7.2 above, if
(i) Executive’s employment terminates for any reason prior to the first year anniversary of the Effective Date; (ii) the Company terminates Executive’s employment for Cause, (iii) Executive resigns Executive’s employment
without Good Reason, or (iv) Executive’s employment terminates due to Executive’s death or disability. 
 8.
Conditions to Receipt of Severance Benefits. To be eligible for the Severance Benefits pursuant to Section 7.2 above, Executive must satisfy the following release requirement (the “Release Requirement”): return to
the Company a signed and dated general release of all known and unknown claims in a termination agreement acceptable to the Company (the “Release”) within the applicable deadline set forth therein, but in no event later than
forty-five (45) calendar days following Executive’s termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the “Release Effective Date”).
No Severance Benefits will be provided hereunder prior to the Release Effective Date. Accordingly, if Executive refuses to sign and deliver to the Company an executed Release or signs and delivers to the Company the Release but exercises
Executive’s right, if any, under applicable law to revoke the Release (or any portion thereof), then Executive will not be entitled to any severance, payment or benefit under this Agreement. 

  
 4. 

 9. Section 409A. It is intended that all of the severance benefits and
other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a
series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company
at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other
agreement with the Company are deemed to be “deferred compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i)
and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month and one day period measured from the
date of Executive’s Separation from Service with the Company, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business
day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 9 shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise
provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the Company determines that any severance benefits provided under this Agreement constitutes “deferred compensation” under
Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective date of the Release will not be deemed to have occurred any earlier than the sixtieth (60th) date following the Separation From Service,
regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for Executive to
execute (and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence until the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or
tax penalties under Code Section 409A, amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the last day of the year following the year in which the expense was incurred and the amount of expenses
eligible for reimbursement (and in-kind benefits provided to Executive) during any one year may not effect amounts reimbursable or provided in any subsequent year. The Company makes no representation that any
or all of the payments described in this Agreement will be exempt from or comply with Code Section 409A and makes no undertaking to preclude Code Section 409A from applying to any such payment. 

10. Definitions. 

10.1 Cause. For the purposes of this Agreement, “Cause” means the occurrence of any one or more of the
following: (i) Executive’s conviction of or plea of guilty or nolo contendere to any felony or any crime of moral turpitude; (ii) Executive’s continued failure or refusal to follow lawful instructions of the Board or
lawful policies and regulations of the 

  
 5. 

 
Company; (iii) Executive’s continued failure to faithfully and diligently perform the assigned duties of Executive’s employment with the Company; (iv) Executive’s
violation of a fiduciary duty or duty or loyalty owed to the Company or its affiliates; (v) unprofessional, unethical, immoral or fraudulent conduct by Executive that materially discredits the Company or its affiliates, or is materially
detrimental to the reputation, character and standing of the Company or its affiliates; or (vi) Executive’s material breach of this Agreement, the Confidential Information Agreement, or any written Company policies. An event described in
Section 10.1(ii) through Section 10.1(vi) herein shall not be treated as “Cause” until after Executive has been given written notice of such event, failure, conduct or breach and Executive fails to cure such event, failure,
conduct or breach within 30 calendar days from such written notice; provided, however, that such 30 calendar day cure period shall not be required if the event, failure, conduct or breach is incapable of being cured. 

10.2 Good Reason. For purposes of this Agreement, Executive shall have “Good Reason” for resignation
from employment with the Company if any of the following actions are taken by the Company without Executive’s prior written consent: (i) a material reduction in Executive’s base salary, unless pursuant to a salary reduction program
applicable generally to the Company’s senior executives; or (ii) a material reduction in Executive’s duties (including responsibilities and/or authorities), provided, however, that a change in job position (including a change
in title) or reporting line shall not be deemed a “material reduction” in and of itself unless Executive’s new duties are materially reduced from the prior duties. In order for Executive to resign for Good Reason, each of the
following requirements must be met: (iii) Executive must provide written notice to the Board within 30 calendar days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive’s resignation,
(iv) Executive must allow the Board at least 30 calendar days from receipt of such written notice to cure such event, (v) such event is not reasonably cured within such 30 calendar day period (the “Cure Period”), and
(vi) Executive must resign from all positions Executive then holds with the Company and its affiliates not later than 30 calendar days after the expiration of the Cure Period. 

11. Dispute Resolution. To ensure the rapid and economical resolution of disputes that may arise in connection with
Executive’s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement,
breach, performance, or interpretation of this Agreement, Executive’s employment with the Company, or the termination of Executive’s employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in San Diego, California by JAMS, Inc. (“JAMS”) or its successors by a single
arbitrator. Both Executive and the Company acknowledge that by agreeing to this arbitration procedure, they each waive the right to resolve any such dispute through a trial by jury or judge or administrative
proceeding. Any such arbitration proceeding will be governed by JAMS’ then applicable rules and procedures for employment disputes, which will be provided to Executive upon request. Questions of whether a claim is subject to arbitration
under this Agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. In any such arbitration, the arbitrator shall: (i) have
the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would 

  
 6. 

 
otherwise be permitted by law; and (ii) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award. Executive and
the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or Executive from obtaining injunctive relief in court to
prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the
arbitrator’s fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. In the event of any such
arbitration, the arbitrator shall (as opposed to may) award the prevailing party his or its costs of arbitration including but not limited to reasonable attorney’s fees; arbitration forum and arbitrator fees; travel expenses; expert fees and
such other usual and customary costs incurred in an arbitration. 
 12. General Provisions. 

12.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery
(including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

12.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

12.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it
shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

12.4 Complete Agreement. This Agreement, together with the Confidential Information Agreement, constitutes the entire
agreement between Executive and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment of the Company’s and Executive’s agreement with regard to this subject matter. This Agreement is
entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes and replaces any other agreements or promises made to Executive by anyone concerning Executive’s
employment terms, compensation or benefits, whether oral or written. It cannot be modified or amended except in a writing signed by a duly authorized officer of the Board, with the exception of those changes expressly reserved to the Company’s
discretion in this Agreement. 
 12.5 Counterparts. This Agreement may be executed in separate counterparts, any one of
which need not contain signatures of more than one party, but both of which taken together will constitute one and the same Agreement. 

  
 7. 

 12.6 Headings. The headings of the sections hereof are inserted for
convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 12.7 Successors and
Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign
any of Executive’s duties hereunder and Executive may not assign any of Executive’s rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

12.8 Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement will be subject to
withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax
treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made
pursuant to this Agreement. 
 12.9 Choice of Law. All questions concerning the construction, validity and
interpretation of this Agreement will be governed by the laws of the State of California. 
 [Signature Page Follows] 

  
 8. 

 IN WITNESS WHEREOF, this
Agreement shall be effective as of the Effective Date 
  

			
	ARS PHARMACEUTICALS, INC.
		
	By:	 	/s/ Richard Lowenthal
		 	 Richard Lowenthal
 Chief Executive
Officer

  

	
	EXECUTIVE
	
	/s/ Sarina Tanimoto
	Dr. Sarina Tanimoto

  
 [SIGNATURE
PAGE TO EMPLOYMENT AGREEMENT] 

 ARS PHARMACEUTICALS, INC. 

AMENDMENT NO. 1 TO 

EXECUTIVE EMPLOYMENT AGREEMENT 

for 
 DR. SARINA TANIMOTO

 This AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this “First Amendment”) is made and entered into as of
September 1, 2021 (the “Effective Date”) by and between ARS Pharmaceuticals, Inc. (the “Company”), and Dr. Sarina Tanimoto (the “Executive”) (the Company and Executive
are hereinafter sometimes individually referred to as a “Party” and together referred to as the “Parties”). 

WHEREAS, Executive and the Company previously entered into that certain Executive Employment Agreement dated as of September 18,
2018 (the “Employment Agreement”); and 
 WHEREAS, Executive and the Company have agreed to amend certain
terms of the Employment Agreement in accordance with the terms hereof. 
 NOW THEREFORE, in consideration of the mutual covenants and
agreements hereinafter set forth, the adequacy and sufficiency of which is hereby acknowledged, the Company and Executive agree as follows: 
 1.
Section 1.1 of the Employment Agreement. Effective as of the Effective Date, Section 1.1 of the Employment Agreement is hereby amended and restated in its entirety to read as follows: 

“Position. Executive shall serve as the Company’s Chief Medical Officer (“CMO”), reporting to the
Company’s Chief Executive Officer. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts, on a full-time (100%) basis, to the business of the Company, except for approved vacation
periods and reasonable periods of illness or other incapacities all in conformity with the Company’s policies applicable to senior executives and general employment policies.” 

2. Section 2.1 of the Employment Agreement. Effective as of the Effective Date, Section 2.1 of the Employment Agreement is hereby amended
and restated in its entirety to read as follows: 
 “Base Salary. Executive shall receive a base salary at the annual rate of
$409,000, less standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule.” 
 3.
Section 6.1 of the Employment Agreement. Effective as of the Effective Date, Section 6.1 of the Employment Agreement is hereby amended and restated in its entirety to read as follows: 

  
 1 

 “Outside Activities. It is understood that Executive is also founder and owner
of Pacific- Link Consulting Inc. (“PLC”) and is permitted to serve in an executive and/or director capacity with PLC so long as such activities do not interfere with the full-time performance of Executive’s duties
hereunder or present a conflict of interest with the Company or its affiliates. Subject to the restrictions set forth herein and the Confidential Information Agreement, and only with prior written disclosure to and consent of the Board, Executive
may engage in other types of business or public activities; provided that the Board may rescind such consent, if the Board determines, in its sole discretion, that such other activities compromise or threaten to compromise the Company’s or its
affiliates’ business interests or conflict with Executive’s duties to the Company or its affiliates.” 
 4. Acknowledgments.
Executive expressly consents to the revised compensation, terms and benefits under this First Amendment. In consideration of the compensation, terms and benefits provided to Executive by this First Amendment and as part of Executive’s
continued employment, Executive agrees and acknowledges that there are no circumstances as of the date of this First Amendment that constitute, and nothing contemplated in this First Amendment shall be deemed for any purpose to be or to create, an
involuntary termination without Cause or a Good Reason resignation right, including for purposes of Section 7.2 of the Employment Agreement, or any other severance or change in control plan, agreement or policy maintained by the Company.
Executive further hereby expressly waives any claim or right Executive may have (if any) to assert that this First Amendment, or any other condition or occurrence, forms the basis for a without Cause termination or Good Reason resignation for any
purpose, including for purposes of Section 7.2 of the Employment Agreement, or any other severance or change in control plan, agreement or policy maintained by the Company. 

5. Effect of Amendment. Except as modified herein, the terms and conditions of the Employment Agreement shall remain unchanged and in full force
and effect. 
 6. Governing Law. This First Amendment shall be governed by the laws of the State of California, without regard to any
conflicts of law principles thereof that would call for the application of the laws of any other jurisdiction. 
 7. Counterparts. This First
Amendment may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic image copies of signatures (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000) or
other transmission method shall be equivalent to original signatures. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, each of the Parties has executed this First Amendment as of the
date first above written. 
  

			
	COMPANY:	 	
	
	ARS PHARMACEUTICALS, INC.

 
			
		
	By:	 	/s/ Richard Lowenthal
		 	 Richard Lowenthal
 Chief Executive
Officer

  

	
	EXECUTIVE:
	
	/s/ Sarina Tanimoto
	Dr. Sarina Tanimoto

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]